SKAN Group AG closes announced increase of its stake in Aseptic Technologies
|
SKAN AG
/ Key word(s): Takeover
Media Information SKAN Group AG closes announced increase of its stake in Aseptic Technologies Allschwil, 4 July 2022 – SKAN Group AG, global market leader in high-quality isolator systems for aseptic production processes in the (bio-)pharmaceutical industry, has completed the announced increase of its shareholding in the Belgian subsidiary Aseptic Technologies. As of July 1, 2022, it acquired a further 20% of the shares from the co-owner, Société Régionale d'Investissement de Wallonie (SRIW), increasing its stake to 80%. Under the contractual agreement with SIRW, SKAN will acquire two subsequent tranches of 5% each between 2023 and 2026. SRIW will remain a 10% shareholder in Aseptic Technologies and will continue to support the company alongside SKAN. Aseptic Technologies is of strategic importance to the SKAN Group. The automated, robotic process solutions for filling closed vials (AT-Closed Vial® Technology) produced by Aseptic Technologies target applications in cell and gene therapy, a rapidly growing therapeutic segment. Customers of Aseptic Technologies have over 300 compounds in research and clinical trials, several of which being in the final phase of development before market approval. The commercialization of new drugs will increase the demand for closed vials and thus the volume in the Services & Consumables segment.
Thomas Balmer, ir@skan.com, +41 79 703 87 28
SKAN is a pioneer in the field of aseptic and aseptic-toxic manufacturing processes for the (bio)pharmaceutical industry. The company is the market and technology leader for high-quality, process-critical isolator systems for filling drugs according to strict sterility standards. In addition, the company offers its customers process support, services and consumables. Innovative solutions and an efficient life-cycle support organization make SKAN an important partner for the pharmaceutical and biotech industry, CMOs (Contract Manufacturing Organizations) and research laboratories worldwide. Founded in 1968, SKAN today employs over 1000 people. More than half of them work at the Allschwil headquarters in the Life Sciences Hub of the Basel region. The other employees are located among the subsidiaries in Switzerland, Germany, Belgium, Japan and the USA. Additional features: File: SKAN_Aseptic Technologies_4.7.2022
End of Media Release |
| Language: | English |
| Company: | SKAN AG |
| Kreuzstrasse 5 | |
| 4123 Allschwil | |
| Switzerland | |
| Phone: | +41 43 268 32 32 |
| E-mail: | ir@skan.com |
| ISIN: | CH0013396012 |
| Valor: | 1339601 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1388319 |
| End of News | EQS News Service |
|
|
1388319 04.07.2022
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.